Goldman Sachs Group Inc Exelixis, Inc. Transaction History

Goldman Sachs Group Inc

  • $605 Billion
  • Q3 2024

A detailed history of Goldman Sachs Group Inc transactions in Exelixis, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 968,510 shares of EXEL stock, worth $34.5 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
968,510
Previous 1,156,809 16.28%
Holding current value
$34.5 Million
Previous $26 Million 3.31%
% of portfolio
0.0%
Previous 0.0%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024
SELL
$21.96 - $27.6 $4.14 Million - $5.2 Million
-188,299 Reduced 16.28%
968,510 $25.1 Million
Q2 2024

Aug 13, 2024
BUY
$20.34 - $23.73 $5.1 Million - $5.94 Million
250,525 Added 27.64%
1,156,809 $26 Million
Q1 2024

May 15, 2024
SELL
$20.17 - $23.93 $2.87 Million - $3.41 Million
-142,525 Reduced 13.59%
906,284 $21.5 Million
Q4 2023

Feb 13, 2024
BUY
$19.25 - $24.13 $112,285 - $140,750
5,833 Added 0.56%
1,048,809 $25.2 Million
Q3 2023

May 14, 2024
SELL
$19.04 - $22.74 $111,060 - $132,642
-5,833 Reduced 0.56%
1,042,976 $22.8 Million
Q3 2023

Nov 14, 2023
BUY
$19.04 - $22.74 $230,612 - $275,426
12,112 Added 1.17%
1,042,976 $22.8 Million
Q2 2023

May 14, 2024
BUY
$18.17 - $20.48 $1.14 Million - $1.29 Million
62,877 Added 6.5%
1,030,864 $19.7 Million
Q2 2023

Aug 14, 2023
BUY
$18.17 - $20.48 $1.14 Million - $1.29 Million
62,877 Added 6.5%
1,030,864 $19.7 Million
Q1 2023

May 14, 2024
SELL
$16.3 - $19.41 $54.9 Million - $65.4 Million
-3,370,235 Reduced 77.69%
967,987 $18.8 Million
Q1 2023

May 11, 2023
SELL
$16.3 - $19.41 $54.9 Million - $65.4 Million
-3,370,235 Reduced 77.69%
967,987 $18.8 Million
Q4 2022

May 14, 2024
SELL
$14.96 - $17.39 $5.98 Million - $6.95 Million
-399,578 Reduced 8.43%
4,338,222 $69.6 Million
Q4 2022

Feb 13, 2023
SELL
$14.96 - $17.39 $5.98 Million - $6.95 Million
-399,578 Reduced 8.43%
4,338,222 $69.6 Million
Q3 2022

May 14, 2024
BUY
$15.68 - $22.27 $5.82 Million - $8.26 Million
370,979 Added 8.5%
4,737,800 $74.3 Million
Q3 2022

Nov 10, 2022
BUY
$15.68 - $22.27 $5.82 Million - $8.26 Million
370,979 Added 8.5%
4,737,800 $74.3 Million
Q2 2022

May 14, 2024
BUY
$17.44 - $23.16 $57.9 Million - $76.8 Million
3,318,012 Added 316.36%
4,366,821 $90.9 Million
Q2 2022

Aug 15, 2022
BUY
$17.44 - $23.16 $19.5 Million - $25.9 Million
1,116,580 Added 34.35%
4,366,821 $90.9 Million
Q1 2022

May 16, 2022
BUY
$17.03 - $22.67 $8.86 Million - $11.8 Million
520,205 Added 19.05%
3,250,241 $73.7 Million
Q4 2021

Feb 14, 2022
BUY
$15.84 - $21.88 $1.4 Million - $1.93 Million
88,229 Added 3.34%
2,730,036 $49.9 Million
Q3 2021

Nov 10, 2021
BUY
$16.3 - $21.14 $43.1 Million - $55.8 Million
2,641,807 New
2,641,807 $55.8 Million

Others Institutions Holding EXEL

# of Institutions
501
Shares Held
244M
Call Options Held
2.54M
Put Options Held
2.29M
View Full List

About EXELIXIS, INC.

EXEL Quotes by TradingView
  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $11.5B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email